{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:00:47Z","timestamp":1780437647781,"version":"3.54.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011912","name":"Washington University School of Medicine in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009340","name":"Children's Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 CA212299"],"award-info":[{"award-number":["K08 CA212299"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.idc.2021.11.004","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T22:10:06Z","timestamp":1644617406000},"page":"125-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiviral Therapeutics in Pediatric Transplant Recipients"],"prefix":"10.1016","volume":"36","author":[{"given":"William R.","family":"Otto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2021.11.004_bib1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2012.08.012","article-title":"Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Srinivasan","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib3","series-title":"Red book: 2021 report of the committee on infectious diseases","first-page":"310","article-title":"Cytomegalovirus infection","year":"2021"},{"key":"10.1016\/j.idc.2021.11.004_bib4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.idc.2021.11.004_bib5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/TP.0000000000001531","article-title":"Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation","volume":"101","author":"Nicastro","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.idc.2021.11.004_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who Is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.idc.2021.11.004_bib8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2011.02.001","article-title":"Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin","volume":"17","author":"Sauter","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1399-3046.2010.01454.x","article-title":"Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation","volume":"15","author":"Martin","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib10","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/TP.0b013e3181a492e8","article-title":"The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation","volume":"87","author":"Danziger-Isakov","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.idc.2021.11.004_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib13","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence","volume":"221","author":"Haidar","year":"2020","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A\u00a0direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib15","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.tp.0000226071.12562.1a","article-title":"Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis","volume":"81","author":"Limaye","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.idc.2021.11.004_bib16","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.idc.2021.11.004_bib17","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.bbmt.2018.05.017","article-title":"Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis","volume":"24","author":"Gagelmann","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmi.2019.09.003","article-title":"Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis","volume":"26","author":"Beyar-Katz","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2021.11.004_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbmt.2005.12.038","article-title":"Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract","volume":"12","author":"Winston","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib20","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2005-09-3786","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.idc.2021.11.004_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1056\/NEJMc1406756","article-title":"CMV prophylaxis in hematopoietic-cell transplantation","volume":"371","author":"Chemaly","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib22","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib23","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100\u00a0mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib27","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.idc.2021.11.004_bib28","first-page":"CD003774","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.idc.2021.11.004_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1399-3062.2011.00689.x","article-title":"Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature","volume":"14","author":"Chawla","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.idc.2021.11.004_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1701302","article-title":"Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study","volume":"22","author":"Moretti","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib33","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/tid.12311","article-title":"The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations","volume":"16","author":"Choi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1399-3062.2012.00760.x","article-title":"Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients","volume":"14","author":"Kim","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib37","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.idc.2021.11.004_bib38","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.idc.2021.11.004_bib39","doi-asserted-by":"crossref","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M; SOLSTICE Trial Investigators. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial. Clin Infect Dis. 2021 Dec 2:ciab988. doi:10.1093\/cid\/ciab988. Epub ahead of print. PMID: 34864943.","DOI":"10.1093\/cid\/ciab988"},{"key":"10.1016\/j.idc.2021.11.004_bib40","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2017.01272","article-title":"Virus-specific T\u00a0cells for the immunocompromised patient","volume":"8","author":"Houghtelin","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.idc.2021.11.004_bib41","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T\u00a0cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.idc.2021.11.004_bib42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.V128.22.61.61","article-title":"Third party CMV-specific cytotoxic T\u00a0cells for treatment of antiviral resistant CMV infection after hematopoietic stem cell transplant [abstract]","volume":"128","author":"Prockop","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.idc.2021.11.004_bib43","doi-asserted-by":"crossref","first-page":"e13526","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Lee","year":"2019","journal-title":"Clin Tansplant"},{"key":"10.1016\/j.idc.2021.11.004_bib44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/ajt.14192","article-title":"Preventive strategies against cytomegalovirus and incidence of alpha-herpesvirus infections in solid organ transplant recipients: A Nationwide Cohort Study","volume":"17","author":"Martin-Gandul","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib45","series-title":"Red book: 2021 report of the committee on infectious diseases","first-page":"437","article-title":"Herpes Simplex","year":"2021"},{"key":"10.1016\/j.idc.2021.11.004_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2021.11.004_bib47","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1086\/342965","article-title":"Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation","volume":"186","author":"Fiddian","year":"2002","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib48","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/pbc.21638","article-title":"Valacyclovir and acyclovir pharmacokinetics in immunocompromised children","volume":"51","author":"Bomgaars","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.idc.2021.11.004_bib49","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/tri.13142","article-title":"Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study","volume":"31","author":"Ariza-Heredia","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.idc.2021.11.004_bib50","doi-asserted-by":"crossref","first-page":"e13622","DOI":"10.1111\/ctr.13622","article-title":"Varicella zoster virus in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Pergam","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib51","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/tid.12180","article-title":"Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity","volume":"16","author":"Vermont","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib52","series-title":"Red book: 2021 report of the committee on infectious diseases","first-page":"869","article-title":"Varicella-Zoster Virus Infections","year":"2021"},{"key":"10.1016\/j.idc.2021.11.004_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2021.11.004_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/jpids\/piy049","article-title":"Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric hematopoietic cell transplant recipients","volume":"8","author":"Fisher","year":"2019","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.idc.2021.11.004_bib55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tid.12022","article-title":"European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011)","volume":"14","author":"Matthes-Martin","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib56","doi-asserted-by":"crossref","first-page":"e13527","DOI":"10.1111\/ctr.13527","article-title":"Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Florescu","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib57","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/514978","article-title":"Disseminated adenovirus disease in immunocompromised and immunocompetent children","volume":"27","author":"Munoz","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib58","doi-asserted-by":"crossref","first-page":"758","DOI":"10.12688\/f1000research.8374.2","article-title":"Use of cidofovir in pediatric patients with adenovirus infection","volume":"5","author":"Ganapathi","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.idc.2021.11.004_bib59","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1111\/ajt.13486","article-title":"The Impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation","volume":"15","author":"Martin-Gandul","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1399-3046.2010.01296.x","article-title":"Long-term impact of respiratory viral infection after pediatric lung transplantation","volume":"14","author":"Liu","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/jpids\/piy024","article-title":"A\u00a0multicenter consortium to define the epidemiology and outcomes of pediatric solid organ transplant recipients with inpatient respiratory virus infection","volume":"8","author":"Danziger-Isakov","year":"2019","journal-title":"J\u00a0Pediatr Infect Dis Soc"},{"key":"10.1016\/j.idc.2021.11.004_bib62","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1399-3062.2009.00397.x","article-title":"Respiratory viral infections within one year after pediatric lung transplant","volume":"11","author":"Liu","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib63","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/ciy294","article-title":"A\u00a05-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients.","volume":"67","author":"Kumar","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib64","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1473-3099(10)70133-X","article-title":"Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study","volume":"10","author":"Kumar","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib65","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3324\/haematol.2011.041913","article-title":"Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients","volume":"96","author":"Ljungman","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.idc.2021.11.004_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/cid\/ciq104","article-title":"Humoral response to the influenza A H1N1\/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients","volume":"52","author":"Manuel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib67","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41409-019-0728-5","article-title":"Immunogenicity of the inactivated influenza vaccine in children who have undergone allogeneic haematopoietic stem cell transplant","volume":"55","author":"Ryan","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib68","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib69","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib70","doi-asserted-by":"crossref","first-page":"e13309","DOI":"10.1111\/tid.13309","article-title":"Prophylactic oseltamivir during major seasonal influenza H1N1 outbreak might reduce both H1N1 and associated pulmonary aspergillosis in children undergoing haploidentical transplantation","volume":"22","author":"Jaiswal","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib71","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3851\/IMP2192","article-title":"Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients","volume":"17","author":"Ison","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.idc.2021.11.004_bib72","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199910283411802","article-title":"Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza","volume":"341","author":"Hayden","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib73","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1056\/NEJM200011023431801","article-title":"Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group","volume":"343","author":"Hayden","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2021.11.004_bib74","doi-asserted-by":"crossref","first-page":"e13511","DOI":"10.1111\/ctr.13511","article-title":"RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib75","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib76","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1399-3062.2008.00362.x","article-title":"Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Khanna","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pbc.23417","article-title":"Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation","volume":"59","author":"Fisher","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.idc.2021.11.004_bib78","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/cid\/ciy413","article-title":"Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus-associated Deaths in Pediatric Patients in Canada, 2003-2013","volume":"68","author":"Tam","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib79","doi-asserted-by":"crossref","first-page":"e13336","DOI":"10.1111\/petr.13336","article-title":"Risk stratification of immunocompromised children, including pediatric transplant recipients at risk of severe respiratory syncytial virus disease","volume":"23","author":"Science","year":"2019","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib80","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/bmt.2016.124","article-title":"RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation","volume":"51","author":"El-Bietar","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib81","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1093\/cid\/ciz1166","article-title":"A\u00a0phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients","volume":"71","author":"Chemaly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib82","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1097\/MPH.0000000000000086","article-title":"Respiratory syncytial virus infections in children with cancer","volume":"36","author":"Chemaly","year":"2014","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.idc.2021.11.004_bib83","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/thoraxjnl-2013-203581","article-title":"Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study","volume":"69","author":"Bridevaux","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.idc.2021.11.004_bib84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.idc.2021.11.004_bib85","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ppul.23561","article-title":"Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease","volume":"51","author":"Pignotti","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.idc.2021.11.004_bib86","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.bbmt.2016.07.005","article-title":"Restrictive palivizumab use does not lead to increased morbidity and mortality in pediatric hematopoietic stem cell transplantation patients","volume":"22","author":"Teusink-Cross","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib87","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/sj.bmt.1701959","article-title":"Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant patients testing positive for RSV","volume":"24","author":"Adams","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl","key":"10.1016\/j.idc.2021.11.004_bib88","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1053\/bbmt.2001.v7.pm11777099","article-title":"Preemptive treatment of pediatric bone marrow transplant patients with asymptomatic respiratory syncytial virus infection with aerosolized ribavirin","volume":"7","author":"Adams","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2021.11.004_bib89","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dkt111","article-title":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections","volume":"68","author":"Shah","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2021.11.004_bib90","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2010-08-263400","article-title":"Management of RSV infections in adult recipients of hematopoietic stem cell transplantation","volume":"117","author":"Shah","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.idc.2021.11.004_bib91","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/tid.12092","article-title":"Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients","volume":"15","author":"Gueller","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib92","doi-asserted-by":"crossref","first-page":"e12844","DOI":"10.1111\/tid.12844","article-title":"Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature","volume":"20","author":"Trang","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib93","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/tid.12510","article-title":"Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative","volume":"18","author":"Beaird","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.idc.2021.11.004_bib94","series-title":"Ganciclovir injection","year":"2017"},{"key":"10.1016\/j.idc.2021.11.004_bib95","series-title":"Valcyte (valganciclovir)","year":"2020"},{"key":"10.1016\/j.idc.2021.11.004_bib96","series-title":"Zovirax (acyclovir sodium)","year":"2005"},{"key":"10.1016\/j.idc.2021.11.004_bib97","series-title":"Valtrex (valacyclovir hydrochloride) Caplets","year":"2008"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000933?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552021000933?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:30:46Z","timestamp":1760196646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552021000933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0891552021000933"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2021.11.004","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiviral Therapeutics in Pediatric Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}